Uncertainty Hinders Compliance With EU Rules On Biological Resources Used In R&D
Attorney Bart Van Vooren explains why pharmaceutical and medical device companies are finding it difficult to comply with the Nagoya Protocol and why they must get involved with the drafting of coming guidelines in this guest column.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.